Cash-Pay or Insurance: The Number That Decides It

Most people frame this as a price comparison: the cash price against the copay, lower one wins. That framing loses money, because the two payments do different work. Insured spending fills a bucket that eventually stops overflowing. Cash spending fills nothing.

Here is the mechanism, and then where the decision actually turns.

What cash-pay costs, from the manufacturers themselves

Both manufacturers now sell direct, and both publish the numbers.

NovoCare's self-pay footnotes: new patients pay $199 a month for two monthly fills through 31 December 2026, then $349 a month for the standard injection strengths and $399 for the Wegovy HD presentation. Ozempic runs the same two-fill structure to $349, or $499 at the highest strength. The tablet products are $149 a month, with one strength holding that rate only until 31 August 2026 before moving to $199.¹

Lilly's published regular self-pay prices for a one-month supply of the Zepbound KwikPen, across the six strengths lowest to highest: $299 · $399 · $499 · $699 · $699 · $699.²

These are real, checkable, first-party numbers, and they are a long way below list. They are also unconditional in a way an insurance benefit is not: nothing has to be approved, no tier has to be favourable, no deductible has to be met.

What insured spending buys that cash does not

A ceiling.

For a 2026 Marketplace plan, the out-of-pocket limit "can't be more than $10,600 for an individual and $21,200 for a family." Once you hit it, "your health plan pays 100% of the costs of covered benefits."³

For Medicare Part D in 2026, CMS publishes the structure directly: a $615 annual deductible, then 25% coinsurance, then no enrollee cost sharing at all once annual out-of-pocket spending reaches $2,100.⁴ That threshold is $2,100, not $2,000 — CMS describes it as the 2025 cap adjusted for the increase in average expenditures for covered Part D drugs, and states that plans may not set it lower.⁴

That ceiling is the entire value proposition of the insured route, and it is why the comparison is not price against price.

The sentence that decides the whole question

HealthCare.gov lists what the out-of-pocket limit does not include. Premiums, out-of-network care, charges above the allowed amount, and: "anything you spend for services your plan doesn't cover."³

Medicare.gov makes the same point about discount routes, in its own words: "TrumpRx and other types of discount cards aren't considered creditable coverage. When you use them (instead of your Medicare plan) to buy drugs, it doesn't count toward your Medicare deductible or out-of-pocket maximum."⁵

Novo says it about its own savings offer: "This offer operates outside of any third-party insurance. The money spent and discounts on your prescription will not count toward your deductible or out-of-pocket requirements and cannot be submitted for reimbursement to your insurer."⁶

Three different publishers, one mechanism. Cash spending is not a smaller version of insured spending. It is a separate ledger, and it never reaches the ceiling.

Medicare's own worked example

The Medicare GLP-1 Bridge, running from 1 July 2026 through 31 December 2027, shows both halves at once.

Medicare.gov gives the beneficiary cost as a $50 monthly copayment for the covered GLP-1s — with a device carve-out worth noticing: Zepbound is covered "KwikPen only. The program doesn't cover single-dose Zepbound vials or pens."⁵

CMS's guidance to Part D sponsors gives the other half: manufacturers supply at "a net price of $245 per monthly supply," and because the Bridge sits outside the Part D payment flow, "no part of the $245 net price... counts toward an eligible beneficiary's gross covered prescription drug costs, and no part of the $50 copay counts toward the beneficiary's true out-of-pocket costs."⁷

Run the arithmetic both ways.

$50 × 12 = $600 a year on the Bridge, and your Part D meter has not moved.

$2,100 is the point at which Part D stops charging you for everything.

If the GLP-1 is your only significant drug cost, $600 beats any route to $2,100 and it is not close. If you have other drug spending that would have carried you to the threshold anyway, the Bridge's $600 is $600 that buys none of the relief waiting at the top.

CMS also excludes anyone whose plan could already cover the drug: beneficiaries "currently eligible for GLP-1 coverage through the Medicare Part D benefit, regardless of whether it is on the beneficiary's Part D plan's formulary, are not eligible" for the Bridge.⁷ So this is frequently not a choice at all. We unpack that in what "covered" actually promises.

The telehealth version of the same trade

Found states the cash-pay case cleanly on its own pricing page: "With cash-pay, you pay a flat monthly price with no copay or deductible involved."⁸ That is the honest pitch — predictability, bought by giving up the ceiling.

Calibrate sits on the other side, selling insurance navigation rather than a drug, and quotes what a commercially insured member typically pays: copays "typically $25/month or less after any deductible is met."⁹ Two conditionals in one sentence — typically, and after. Both matter.

Where the crossover sits

Four questions, in order. They resolve most cases.

Will my plan actually cover it — formulary, tier, prior authorization? If no, the comparison is over: cash-pay is the only route with a price.

Will I hit my out-of-pocket maximum this year on other care? If yes, insured spending on the GLP-1 is doing double duty and cash spending is not.

Have I met my deductible? Before it, a covered drug can cost full price anyway, and a cash price can be lower than a "covered" one.

Am I eligible for a manufacturer card, and what does it cap? Cards have their own limits, and government-insured patients are excluded by name — see copay cards: the cap is the product.

When cash-pay is obviously right

When the plan does not cover it. When the drug is your only meaningful health spending this year. When the cash price is below your coinsurance share of the covered price. And when predictability is worth more to you than a ceiling you were never going to reach.

None of that is a small set of people. It is simply a different decision from the one the price comparison implies, and it is the reason our provider boards are built on twelve-month totals rather than monthly headlines — start with compounded semaglutide or compounded tirzepatide.